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ABSTRACT
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, 
and prednisone (R-CHOP) is currently the most widely used first-line therapy 
for aggressive B-cell lymphomas. However, many patients, including those 
with organ dysfunction, may not tolerate the toxicities associated with this 
regimen. Recent data from the phase III study group indolent lymphomas 
(StiL) non-Hodgkin lymphoma (NHL)-1 trial suggested that bendamustine plus 
rituximab were superior in effectiveness and tolerability compared to R-CHOP 
in the treatment of indolent and mantle cell lymphomas. Preliminary study 
has indicated the effective use of bendamustine alone or in combination in 
the treatment of aggressive B-cell lymphomas as well. A 70-year-old male 
with heavily treated relapsed diffuse large B-cell lymphoma (DLBCL) showed 
complete remission (CR) after receiving 8 cycles of rituximab in combination 
with bendamustine as 3rd line treatment. Bendamustine has demonstrated 
considerable efficacy and well-tolerated therapy in relapsed DLBCL patients. 
Our case report demonstrated that treating patients with bendamustine-
based regimen, even in the setting of organ impairment and elderly is safe 
and effective. Given the increasing evidence of its effectiveness, further 
investigation of bendamustine’s safety and tolerability aspects in special 
groups is recommended such as those with renal impairment.
ABSTRAK
Rituximab yang dikombinasikan dengan siklofosfamid, doksorubisin, 
vinkristin, dan prednison (R-CHOP) merupakan terapi lini pertama yang 
paling banyak digunakan untuk limfoma sel-B agresif. Namun, banyak pasien, 
termasuk mereka yang mengalami disfungsi organ, tidak mentolerir efek toksik 
terkait dengan rejimen ini. Data terbaru dari kelompok studi fase III limfoma 
yang berkembang lambat (StiL) non-Hodgkinlymphoma (NHL)-1 menunjukkan 
bahwa bendamustine plus rituximab lebih efektif dan ditolerir dibandingkan 
R-CHOP dalam pengobatan sel limfoma yang berkembang lambat dan mantel 
sel limfoma. Penelitian pendahuluan menunjukkan efektivitas penggunaan 
bendamustine secara tunggal atau kombinasi dalam pengobatan limfoma 
sel B yang agresif. Seorang laki-laki berusia 70 tahun dengan limfoma sel B 
besar (DLBCL) menunjukkan remisi lengkap (CR) setelah menerima 8 siklus 
rituximab dalam kombinasi dengan bendamustine sebagai pengobatan 
lini ke-3. Bendamustine menunjukkan efektivitas yang cukup besar dan 
ditoleransi dengan baik pada pasien DLBCL yang kambuh. Laporan kasus 
kami menunjukkan bahwa terapi pasien DLBCL dengan rejimen berbasis 
bendamustine efektif dan aman, bahkan pada pasien usia lanjut dengan 
gangguan fungsi organ. Mengingat semakin banyak bukti efektivitasnya, 
penelitian lebih lanjut tentang keamanan dan tolerabilitas bendamustine pada 
kelompok khusus direkomendasikan, seperti pasien dengan gangguan ginjal.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) 
is an aggressive subtype of non-Hodgkin 
lymphoma (NHL) which commonly occurs 
in older patients, with median age of 70 
years at diagnosis.1,2   The combination 
of rituximab with cyclophosphamide, 
doxorubicin, vincristine and prednisone 
(R-CHOP) is the  standard   first   line 
treatment  regimen in patients with 
CD20+ DLBCL. However, most of the 
evidence supporting the use of R-CHOP 
apply to patients younger than 80 years 
with limited comorbidities, thus many 
of the elderly and frail patients might be 
classified as unsuitable for this regimen.3-5 
Furthermore, many of the reduced-dose 
variant of this regimen still associated 
with intolerable toxicities for elderly.4,6,7
Bendamustine is a worldwide 
approved cytotoxic alkylating agent 
and used for treating a number of 
lymphoid malignancies (chronic 
lymphocytic leukemia and other indolent 
NHL) in Europe and the US.8 The drug 
consists of an alkylating nitrogen 
mustard groupbound to a purine-like 
benzimidazole  ring.9-11 Preclinical   studies 
and clinical observations suggested that 
bendamustine has limited cross-resistance 
with other alkylating agents. In addition, 
it demonstrates significant synergism 
with anti-CD20 monoclonal antibody 
rituximab andpurine analogues.12,13 Based 
on two multicenter randomized studies, 
bendamustine has received  approval for 
second-line therapy in relapsed/refractory 
indolent NHL.11,14
A growing  body of evidence suggested 
good efficacy and acceptable tolerability of 
bendamustine as the first-line option for 
indolent lymphoma, mantle cell lymphoma 
(MCL), and selected patients with 
aggressive lymphoma.15,16 Consequently, 
bendamustine-rituximab (BR) was tested 
in DLBCL patients, initially in relapse/
refractory settings and then also as first-
line treatment.17-19 Here we reported the 
safe and effective use of bendamustine in 
combination with rituximab for second 
relapse DLBCL case in a frail elderly 
with several comorbidities who received 
prior R-CHOP treatment.
CASE REPORT
In January 2011, a 72-years-old male 
presented with enlarged cervical mass 
with B symptoms for 2 months (FIGURE 
1). Biopsy of the mass was performed 
and he was diagnosed with Ann Arbor 
stage 3, CD20 (+), high grade DLBCL. His 
baseline LDH was 675 with performance 
status of class 1 eastern cooperative 
oncology group (ECOG). During March 
until September 2011, he was treated 
with 8 cycles of R-CHOP chemotherapy 
every 3 weeks, which comprised of 
rituximab 375 mg/m2, cyclophosphamide 
750 mg/m2, doxorubicin 50 mg/m2, 
vincristine 1.4 mg/m2, and prednisone 80 
mg/m2. He achieved complete response 
upon completion of chemotherapy. Six 
years later he experienced locoregional 
recurrence and was treated with 3 
cycles R-CHOP chemotherapy. He did 
not receive full regimen of 6 cycles due 
to worsening of renal function after the 
third cycle (glomerular filtration rate 
of 33 mL/min/1.73 m2). Nevertheless, 
he achieved complete response after 3 
cycles of R-CHOP.
In June 2019, he experienced 
second locoregional recurrence and was 
prescribed a third line chemotherapy 
regimen of bendamustine 90 mg/m2 and 
rituximab 375 mg/m2(FIGURE 2). The 
patient experienced no adverse event 
and achieved complete remission (CR) 
after 8 cycles of chemotherapy (FIGURE 
3).  The patient remained in CR at 7-month 
post treatment follow-up (FIGURE 4).
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FIGURE 1. Cervical ultrasonography performed before initiation of rituximab-
bendamustinein May 2019. Multiple enlarged cervical lymph nodes 
were observed on right mid-jugular (left) and right-supraclavicular 
(right) cervical region.
FIGURE 2. Sagittal (a), transverse (b), and coronal (c) view of cervical MSCT 
performed after 8 cycles of BR (May 2020) revealed no evidence of 
lymph node enlargement.
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FIGURE 3. Sagittal (a), transverse (b), and coronal (c) view of cervical MSCT 
performed7 months after completion of BR (August 2020) revealed 
no evidence of lymph node enlargement.
FIGURE 4. Timeline showing patient’s course of disease.
DISCUSSION
We reported a case of relapsed 
DLBCL in frail elderly patient who 
achieved CR after 8 cycles of rituximab 
and bendamustine. He had sustained 
remission with no sign of disease 
recurrence at 7 months follow-up.
Treatment outcomes for DLBCL 
patients have significantly improved 
since  the introduction of R-CHOP 
regimen. However, up to 40% of 
patients with DLBCL do not achieve 
durable remission, requiring multiple 
lines of chemotherapy regimens.10,14 
Unfortunately, standard therapies, 
such as R-CHOP and rituximab, 
cyclophosphamide, vincristine, and 
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prednisone (R-CVP) are associated with 
multiple toxicities such as peripheral 
neuropathy, cardiac toxicities, myelo-
suppression, and alopecia. This presents 
a challenge in elderly patients which 
have decreased physiologic function and 
might not able to tolerate side-effects 
associated with R-CHOP. Our patient 
showed excellent response towards 
the first cycle of R-CHOP without any 
noticeable adverse event. He received 
another cycle of R-CHOP after the first 
locoregional recurrence and showed 
another CR. We chose to re-prescribe 
R-CHOP for this patient due to his 
extended period of remission (6 years) 
before recurrence, unfortunately he 
experienced renal function deterioration 
which prevented him from receiving full 
cycle.16
Bendamustine-based regimens, such 
as BR, can be considered as an option 
in the management of relapsed DLBCL. 
In randomized phase 3 clinical trials, 
bendamustine in combination with 
rituximab demonstrated efficacy and 
acceptable safety profiles compared with 
standard frontline regimens for indolent 
B cell NHL and mantle-cell lymphoma 
(the StiL study and the BRIGHT study).12-15 
Hammersen et al.20 in retrospective 
analysis confirms R-B and R-mini-CHOP 
as reasonable treatment options for 1st 
line treatment of elderly and comorbid 
DLBCL-patients. Toxicity was well 
manageable in both treatment arms. 
Superior hematologic tolerability of R-B 
compared to R-mini-CHOP warrants a 
treatment recommendation in particular 
for patients with impaired hematologic 
reserve.21   Hong et al.22  confirmed  the 
high efficacy and acceptable toxicity 
profile of BR in relapsed or refractory 
DLBCL patients in multicenter 
retrospective analysis of  58 patients. 
The median progression  free survival 
was 3.9 months (95% confidence  interval 
[CI]: 2.4–5.4 months), and the median 
overall survival was 6.7 months (95% CI: 
4.7–8.7 months).22 Increasing interest in 
BR as an upfront therapy has prompted 
a cost effectiveness analysis of this drug. 
When compared to RCHOP or RCVP 
regimens, the BR was found to be cost-
effective, and due to its more favorable 
toxicity profile it incurred lower costs 
related to adverse event management. 
Therefore, BR seems to possibly evolve 
to a therapeutic option in frail or slow-go 
DLBCL patients.9,12,18
CONCLUSION
We observed excellent response and 
tolerability of bendamustine-rituximab 
regimen given to relapsed elderly DLBCL 
patient. Given the increasing evidence of 
its effectiveness, further understanding 
of bendamustine’s safety and tolerability 
in special population, such as those with 
renal impairment, is crucial.
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